Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.

Purpose: Cystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with ≥ 1 F508del allele during ETI therapy. The device's suitability for home monitoring of therapy success was also assessed.

Methods: In a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One + at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.

Results: Significant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1-5 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.

Conclusion: Sleepiz One + reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.